New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
15:28 EDTNSPHNanosphere receives FDA clearance for C. difficile test
Nanosphere announced the FDA granted 510(k) clearance permitting marketing of its C.difficile test on the automated sample-to-result Verigene System. The C. difficile test expands Nanosphere's infectious disease test capabilities. C. difficile infection is a cause of diarrhea that can lead to colitis, other serious intestinal conditions and death. In less than two hours, the C. difficile test detects the toxin A and B gene sequences of C. difficile and identifies the PCR ribotype 027 strain which is associated with increased severity of disease and used for infection control. Early and accurate diagnosis of C. difficile infections is critical in both the proper treatment of infected patients and subsequent implementation of isolation and containment procedures to prevent further spread of the infection.
News For NSPH From The Last 14 Days
Check below for free stories on NSPH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
06:06 EDTNSPHNanosphere receives deficiency letter from Nasdaq
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use